{
    "info": {
        "nct_id": "NCT02873195",
        "official_title": "BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer",
        "inclusion_criteria": "* Histologically confirmed colorectal cancer that is either clinically or histologically proven to be metastatic and has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, bevacizumab and an anti-EGFR antibody (if tumor is RAS wild-type), or where the treatment was not tolerated or contraindicated\n* Measurable disease; Note: previously irradiated sites can be included if there is documented disease progression in that site\n* Capecitabine and bevacizumab considered appropriate treatment for the patient\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Absolute neutrophil count >= 1,500/uL (obtained =< 7 days prior to randomization)\n* Platelets >= 100,000/uL (obtained =< 7 days prior to randomization)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (obtained =< 7 days prior to randomization); patients with known Gilbert?s syndrome who have serum bilirubin =< 3 X ULN may enroll\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases (obtained =< 7 days prior to randomization)\n* Hemoglobin >= 9 g/dL continuation of erythropoietin products is permitted (obtained =< 7 days prior to randomization); hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level\n* Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula or a 24 hour urine (obtained =< 7 days prior to randomization)\n* The following laboratory values obtained =< 14 days prior to randomization\n\n  * Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated; within local institutional guidelines per local physician if anticoagulated\n* Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only\n* Provide informed written consent\n* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willingness to provide tissue and blood samples for correlative research purposes\n* Life expectancy of >= 3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug; medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use; postmenopausal woman must have been amenorrheic for at least 2 years to be considered of non-childbearing potential; sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug\n* Chemotherapy, biologic anti-cancer therapy, or central field radiation therapy =< 28 days prior to randomization; Note: local or stereotactic radiation =< 14 days prior to randomization\n* Any investigational agent =< 28 days or 5 half-lives prior to randomization (whichever is longer)\n* Prior treatment with atezolizumab or another PD-L1/PD-1 therapy\n* History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager\n* Known untreated central nervous system (CNS) metastases; Note: patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for this purpose =< 30 days prior to randomization\n* Inadequately controlled hypertension (defined as average systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)\n* History of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\n* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery =< 12 months prior to randomization\n* Active coronary heart disease evidenced as angina or requiring medications to prevent angina\n* History of stroke or transient ischemic attack, or other arterial thrombosis =< 12 months prior to randomization\n* Symptomatic peripheral vascular disease\n* Any other significant vascular disease (e.g., aortic aneurysm, aortic dissection, or carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting)\n* Any previous National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 venous thromboembolism\n* Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician\n* History of active gastrointestinal (GI) bleeding or other major bleeding =< 12 months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded\n* Major surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomization\n* Anticipation of need for major surgical procedure =< 6 months after randomization\n* Minor surgical procedure =< 7 days prior to randomization; exception: insertion of an indwelling catheter or percutaneous needle biopsy =< 48 hours prior to randomization\n* History of intra-abdominal abscess =< 6 months prior to randomization; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll\n* History of abdominal or other significant fistula, gastrointestinal or other organ perforation; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll\n* Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician\n* Known proteinuria defined by >= 2+ protein by urinalysis (UA) or >= 1 gram protein by 24 hour urine collection; Note: Subjects that are >= 2+ or greater on dipstick but < 1 g protein on 24 hour urine ARE eligible to participate\n* Intolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab (e.g., arterial thromboembolism [ATE], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome [RPLS]); Note: patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physician\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency\n* Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption\n* Active inflammatory bowel disease\n* History of diverticulitis, chronic ulcerative lower GI disease such as Crohn?s disease or ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforations\n* History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener?s granulomatosis, Sjogren?s syndrome, Bell?s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; Note: patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study\n* Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and human immunodeficiency virus (HIV), but excluding fungal infections of nail beds\n* Vaccination with a live or attenuated vaccine =< 28 days prior to randomization; Note: other types of vaccines, including inactivated/killed, toxoid (inactivated toxoid), and subunit/conjugate are all permitted at any time\n* Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< 1 except neuropathy\n* Other concurrent severe and/or uncontrolled medical disease, psychiatric illness, or social situation, which could compromise safety of treatment as so judged by the treating physician; Note: this includes but is not limited to: severely impaired lung function, uncontrolled diabetes (history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL), severe infection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, chronic liver or renal disease, and active upper GI tract ulceration\n* Unwilling to or unable to comply with the protocol\n* Current or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day)\n* Current or recent (=< 10 days prior to randomization) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes, unless the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of randomization; Note: the use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants >= 14 days at the time of randomization; prophylactic use of anticoagulants is allowed\n* History or recent diagnosis of demyelinating disease\n* History of other carcinoma =< 3 years; exception: if risk of recurrence is known to be under 5% at time of randomization\n* Current or recent (=< 90 days prior to randomization) endoluminal stent in the stomach, bowel, colon or rectum\n* Colonoscopy, sigmoidoscopy, or proctoscopy =< 7 days prior to randomization\n* Current or recent (=< 28 days prior to randomization) use of sorivudine, brivudine, and St. John?s wort\n* Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation\n* Prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) =< 14 days prior to randomization; exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible; the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated; within local institutional guidelines per local physician if anticoagulated",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "anticoagulation status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "anticoagulation status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 X ULN if not anticoagulated",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "anticoagulation status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "within local institutional guidelines per local physician if anticoagulated",
                    "criterion": "coagulation parameters (PT, PTT, INR)",
                    "requirements": [
                        {
                            "requirement_type": "anticoagulation status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": "within local institutional guidelines per local physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provide informed written consent",
            "criterions": [
                {
                    "exact_snippets": "Provide informed written consent",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL continuation of erythropoietin products is permitted (obtained =< 7 days prior to randomization); hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL ... hemoglobin must be stable >= 9 g/dL >= 14 days without blood transfusion to maintain hemoglobin level",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "blood transfusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,500/uL (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/uL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "absolute neutrophil count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula or a 24 hour urine (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance must be >= 50 ml/min",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "using the Cockcroft-Gault formula or a 24 hour urine",
                    "criterion": "method of creatinine clearance calculation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "Cockcroft-Gault formula",
                                "24 hour urine"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "24 hour urine (obtained =< 7 days prior to randomization)",
                    "criterion": "timing of 24 hour urine collection",
                    "requirements": [
                        {
                            "requirement_type": "time since collection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
            "criterions": [
                {
                    "exact_snippets": "Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                    "criterion": "willingness to return to enrolling institution for follow-up",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "active monitoring phase of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases (obtained =< 7 days prior to randomization)",
                    "criterion": "aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity with hepatic metastases",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 3,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "timing of AST/ALT measurement",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Capecitabine and bevacizumab considered appropriate treatment for the patient",
            "criterions": [
                {
                    "exact_snippets": "Capecitabine and bevacizumab considered appropriate treatment for the patient",
                    "criterion": "capecitabine and bevacizumab treatment appropriateness",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/uL (obtained =< 7 days prior to randomization)",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "obtained =< 7 days prior to randomization",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time since measurement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease; Note: previously irradiated sites can be included if there is documented disease progression in that site",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously irradiated sites can be included if there is documented disease progression in that site",
                    "criterion": "previously irradiated sites",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "if there is documented disease progression"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 X upper limit of normal (ULN) (obtained =< 7 days prior to randomization); patients with known Gilbert?s syndrome who have serum bilirubin =< 3 X ULN may enroll",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 X upper limit of normal (ULN) (obtained =< 7 days prior to randomization)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timing of measurement",
                            "expected_value": "obtained within 7 days prior to randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert?s syndrome who have serum bilirubin =< 3 X ULN may enroll",
                    "criterion": "serum bilirubin in patients with known Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "known Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed colorectal cancer that is either clinically or histologically proven to be metastatic and has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, bevacizumab and an anti-EGFR antibody (if tumor is RAS wild-type), or where the treatment was not tolerated or contraindicated",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed colorectal cancer",
                    "criterion": "colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically or histologically proven to be metastatic",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "clinically proven",
                                "histologically proven"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine)",
                    "criterion": "prior fluoropyrimidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression on treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on regimens containing ... oxaliplatin",
                    "criterion": "prior oxaliplatin treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression on treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on regimens containing ... irinotecan",
                    "criterion": "prior irinotecan treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression on treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on regimens containing ... bevacizumab",
                    "criterion": "prior bevacizumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression on treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed on regimens containing ... an anti-EGFR antibody (if tumor is RAS wild-type)",
                    "criterion": "prior anti-EGFR antibody treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression on treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "RAS mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "or where the treatment was not tolerated or contraindicated",
                    "criterion": "prior treatment tolerance or contraindication",
                    "requirements": [
                        {
                            "requirement_type": "treatment tolerance or contraindication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to provide tissue and blood samples for correlative research purposes",
            "criterions": [
                {
                    "exact_snippets": "Willingness to provide tissue ... for correlative research purposes",
                    "criterion": "tissue sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness to provide ... blood samples for correlative research purposes",
                    "criterion": "blood sample provision",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of >= 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of >= 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The following laboratory values obtained =< 14 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "laboratory values obtained =< 14 days prior to randomization",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only",
            "criterions": [
                {
                    "exact_snippets": "Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "women of childbearing potential only"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager",
            "criterions": [
                {
                    "exact_snippets": "History of allergic reactions attributed to therapeutic antibodies",
                    "criterion": "allergic reactions to therapeutic antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccination with a live or attenuated vaccine =< 28 days prior to randomization; Note: other types of vaccines, including inactivated/killed, toxoid (inactivated toxoid), and subunit/conjugate are all permitted at any time",
            "criterions": [
                {
                    "exact_snippets": "Vaccination with a live or attenuated vaccine =< 28 days prior to randomization",
                    "criterion": "live or attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day)",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day)",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent (=< 10 days prior to randomization) use of ... clopidogrel (> 75 mg/day)",
                    "criterion": "clopidogrel use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "days prior to randomization"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 75,
                                "unit": "mg/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal or other significant fistula, gastrointestinal or other organ perforation; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal or other significant fistula",
                    "criterion": "fistula",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "abdominal",
                                "other significant"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal or other organ perforation",
                    "criterion": "organ perforation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "gastrointestinal",
                                "other organ"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if the affected area was surgically resected, and there is no further risk to the area, patients may enroll",
                    "criterion": "affected area (of fistula or perforation)",
                    "requirements": [
                        {
                            "requirement_type": "surgical resection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk to area",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other significant vascular disease (e.g., aortic aneurysm, aortic dissection, or carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting)",
            "criterions": [
                {
                    "exact_snippets": "Any other significant vascular disease",
                    "criterion": "significant vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic aneurysm",
                    "criterion": "aortic aneurysm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic dissection",
                    "criterion": "aortic dissection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting",
                    "criterion": "carotid stenosis requiring intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "intervention_required",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active coronary heart disease evidenced as angina or requiring medications to prevent angina",
            "criterions": [
                {
                    "exact_snippets": "Active coronary heart disease evidenced as angina or requiring medications to prevent angina",
                    "criterion": "coronary heart disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "angina",
                                "requiring medications to prevent angina"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke or transient ischemic attack, or other arterial thrombosis =< 12 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... =< 12 months prior to randomization",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... transient ischemic attack ... =< 12 months prior to randomization",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... other arterial thrombosis =< 12 months prior to randomization",
                    "criterion": "arterial thrombosis (other than stroke or TIA)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< 1 except neuropathy",
            "criterions": [
                {
                    "exact_snippets": "Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< 1 except neuropathy",
                    "criterion": "reversible treatment-related toxicity (excluding neuropathy)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "NCI CTCAE grade"
                            }
                        },
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticipation of need for major surgical procedure =< 6 months after randomization",
            "criterions": [
                {
                    "exact_snippets": "Anticipation of need for major surgical procedure =< 6 months after randomization",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months after randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequately controlled hypertension (defined as average systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
            "criterions": [
                {
                    "exact_snippets": "average systolic blood pressure > 150 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "average value",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure > 100 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "average value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) =< 14 days prior to randomization; exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible; the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) =< 14 days prior to randomization",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible",
                    "criterion": "treatment with acute, low-dose, systemic immunosuppressant medications",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
                    "criterion": "use of inhaled corticosteroids and mineral-corticoids for orthostatic hypotension or adrenocortical insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association (NYHA) grade II or greater congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association (NYHA) grade II or greater congestive heart failure",
                    "criterion": "congestive heart failure (NYHA grade)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any previous National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 venous thromboembolism",
            "criterions": [
                {
                    "exact_snippets": "Any previous National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 venous thromboembolism",
                    "criterion": "venous thromboembolism",
                    "requirements": [
                        {
                            "requirement_type": "history of event",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity (CTCAE grade)",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unwilling to or unable to comply with the protocol",
            "criterions": [
                {
                    "exact_snippets": "Unwilling to or unable to comply with the protocol",
                    "criterion": "willingness and ability to comply with the protocol",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic bone marrow transplantation or prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and human immunodeficiency virus (HIV), but excluding fungal infections of nail beds",
            "criterions": [
                {
                    "exact_snippets": "Active current infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of recurrent bacterial, viral, fungal, mycobacterial or other infections",
                    "criterion": "recurrent infections",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and human immunodeficiency virus (HIV)",
                    "criterion": "specific infections (tuberculosis, atypical mycobacterial disease, hepatitis B, hepatitis C, herpes zoster, HIV)",
                    "requirements": [
                        {
                            "requirement_type": "history_or_presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding fungal infections of nail beds",
                    "criterion": "fungal infections of nail beds",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or recent diagnosis of demyelinating disease",
            "criterions": [
                {
                    "exact_snippets": "History or recent diagnosis of demyelinating disease",
                    "criterion": "demyelinating disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recent diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery =< 12 months prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... =< 12 months prior to randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina ... =< 12 months prior to randomization",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac or other vascular stenting ... =< 12 months prior to randomization",
                    "criterion": "cardiac or other vascular stenting",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "angioplasty ... =< 12 months prior to randomization",
                    "criterion": "angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgery =< 12 months prior to randomization",
                    "criterion": "vascular surgery",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of diverticulitis, chronic ulcerative lower GI disease such as Crohn?s disease or ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforations",
            "criterions": [
                {
                    "exact_snippets": "History of diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic ulcerative lower GI disease such as Crohn?s disease or ulcerative colitis",
                    "criterion": "chronic ulcerative lower GI disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Crohn?s disease",
                    "criterion": "Crohn's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other symptomatic lower GI conditions that might predispose to perforations",
                    "criterion": "symptomatic lower GI conditions that might predispose to perforations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of active gastrointestinal (GI) bleeding or other major bleeding =< 12 months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded",
            "criterions": [
                {
                    "exact_snippets": "History of active gastrointestinal (GI) bleeding or other major bleeding =< 12 months prior to randomization",
                    "criterion": "history of active gastrointestinal (GI) bleeding or other major bleeding",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded",
                    "criterion": "predisposing risk factor for bleeding",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known dihydropyrimidine dehydrogenase (DPD) deficiency",
            "criterions": [
                {
                    "exact_snippets": "Known dihydropyrimidine dehydrogenase (DPD) deficiency",
                    "criterion": "dihydropyrimidine dehydrogenase (DPD) deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other carcinoma =< 3 years; exception: if risk of recurrence is known to be under 5% at time of randomization",
            "criterions": [
                {
                    "exact_snippets": "History of other carcinoma =< 3 years",
                    "criterion": "history of other carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "duration since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception: if risk of recurrence is known to be under 5% at time of randomization",
                    "criterion": "risk of recurrence of other carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "risk percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hypertensive crisis or hypertensive encephalopathy",
            "criterions": [
                {
                    "exact_snippets": "History of hypertensive crisis",
                    "criterion": "hypertensive crisis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... hypertensive encephalopathy",
                    "criterion": "hypertensive encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener?s granulomatosis, Sjogren?s syndrome, Bell?s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; Note: patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                    "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener?s granulomatosis",
                    "criterion": "Wegener's granulomatosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Sjogren?s syndrome",
                    "criterion": "Sjogren's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Bell?s palsy",
                    "criterion": "Bell's palsy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Guillain-Barre syndrome",
                    "criterion": "Guillain-Barre syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune thyroid disease",
                    "criterion": "autoimmune thyroid disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vasculitis",
                    "criterion": "vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerulonephritis",
                    "criterion": "glomerulonephritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible",
                    "criterion": "autoimmune-related hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "stable dose of thyroid replacement hormone"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active inflammatory bowel disease",
            "criterions": [
                {
                    "exact_snippets": "Active inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption",
            "criterions": [
                {
                    "exact_snippets": "Impairment of GI function",
                    "criterion": "gastrointestinal (GI) function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "GI disease that may significantly alter capecitabine drug absorption",
                    "criterion": "gastrointestinal (GI) disease",
                    "requirements": [
                        {
                            "requirement_type": "potential to significantly alter capecitabine drug absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomization",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 56,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "open biopsy ... =< 56 days prior to randomization",
                    "criterion": "open biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 56,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury =< 56 days prior to randomization",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 56,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, biologic anti-cancer therapy, or central field radiation therapy =< 28 days prior to randomization; Note: local or stereotactic radiation =< 14 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... =< 28 days prior to randomization",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biologic anti-cancer therapy ... =< 28 days prior to randomization",
                    "criterion": "biologic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "central field radiation therapy =< 28 days prior to randomization",
                    "criterion": "central field radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "local or stereotactic radiation =< 14 days prior to randomization",
                    "criterion": "local or stereotactic radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab (e.g., arterial thromboembolism [ATE], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome [RPLS]); Note: patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Intolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab",
                    "criterion": "intolerance to bevacizumab",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": [
                                "grade 3",
                                "grade 4"
                            ]
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": "bevacizumab"
                        },
                        {
                            "requirement_type": "discontinuation required",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial thromboembolism [ATE], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome [RPLS]",
                    "criterion": "specific bevacizumab-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "arterial thromboembolism",
                                "perforation",
                                "wound healing difficulty",
                                "proteinuria",
                                "reversible posterior leukoencephalopathy syndrome"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physician",
                    "criterion": "bevacizumab-related hypertension",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": "grade 3"
                        },
                        {
                            "requirement_type": "manageability with standard oral antihypertensives",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug; medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use; postmenopausal woman must have been amenorrheic for at least 2 years to be considered of non-childbearing potential; sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug",
                    "criterion": "contraception use (women of child-bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of forms",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "forms"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "from time of initial consent",
                                "for the duration of study participation",
                                "for >= 6 months after the last dose of study drug"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use",
                    "criterion": "contraceptive method (women of child-bearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "acceptable methods",
                            "expected_value": [
                                "surgical sterilization",
                                "approved hormonal contraceptives",
                                "barrier methods with spermicide",
                                "intrauterine device (IUD)"
                            ]
                        },
                        {
                            "requirement_type": "unacceptable methods",
                            "expected_value": [
                                "Plan B (emergency contraception)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "postmenopausal woman must have been amenorrheic for at least 2 years to be considered of non-childbearing potential",
                    "criterion": "postmenopausal status (women)",
                    "requirements": [
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for >= 6 months after the last dose of study drug",
                    "criterion": "contraception use (sexually active men)",
                    "requirements": [
                        {
                            "requirement_type": "number of forms",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "form"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "from time of initial consent",
                                "for the duration of study participation",
                                "for >= 6 months after the last dose of study drug"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other concurrent severe and/or uncontrolled medical disease, psychiatric illness, or social situation, which could compromise safety of treatment as so judged by the treating physician; Note: this includes but is not limited to: severely impaired lung function, uncontrolled diabetes (history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL), severe infection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, chronic liver or renal disease, and active upper GI tract ulceration",
            "criterions": [
                {
                    "exact_snippets": "Other concurrent severe and/or uncontrolled medical disease",
                    "criterion": "concurrent severe and/or uncontrolled medical disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "social situation, which could compromise safety of treatment",
                    "criterion": "compromising social situation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severely impaired lung function",
                    "criterion": "severely impaired lung function",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled diabetes (history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL)",
                    "criterion": "uncontrolled diabetes",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL",
                    "criterion": "blood glucose readings",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 300,
                                        "unit": "mg/dL"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 50,
                                        "unit": "mg/dL"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe infection",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "severe malnutrition",
                    "criterion": "severe malnutrition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ventricular arrhythmias",
                    "criterion": "ventricular arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known active vasculitis of any cause",
                    "criterion": "active vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor invasion of any major blood vessel",
                    "criterion": "tumor invasion of any major blood vessel",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic liver or renal disease",
                    "criterion": "chronic liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic liver or renal disease",
                    "criterion": "chronic renal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active upper GI tract ulceration",
                    "criterion": "active upper GI tract ulceration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minor surgical procedure =< 7 days prior to randomization; exception: insertion of an indwelling catheter or percutaneous needle biopsy =< 48 hours prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Minor surgical procedure =< 7 days prior to randomization",
                    "criterion": "minor surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "insertion of an indwelling catheter or percutaneous needle biopsy =< 48 hours prior to randomization",
                    "criterion": "insertion of an indwelling catheter or percutaneous needle biopsy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 48,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with atezolizumab or another PD-L1/PD-1 therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with atezolizumab",
                    "criterion": "atezolizumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "another PD-L1/PD-1 therapy",
                    "criterion": "PD-L1/PD-1 therapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Colonoscopy, sigmoidoscopy, or proctoscopy =< 7 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Colonoscopy, sigmoidoscopy, or proctoscopy =< 7 days prior to randomization",
                    "criterion": "colonoscopy, sigmoidoscopy, or proctoscopy",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Clinically-significant evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically-significant evidence of ... coagulopathy",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any investigational agent =< 28 days or 5 half-lives prior to randomization (whichever is longer)",
            "criterions": [
                {
                    "exact_snippets": "Any investigational agent =< 28 days or 5 half-lives prior to randomization (whichever is longer)",
                    "criterion": "prior investigational agent use",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or recent (=< 10 days prior to randomization) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes, unless the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of randomization; Note: the use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants >= 14 days at the time of randomization; prophylactic use of anticoagulants is allowed",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (=< 10 days prior to randomization) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes",
                    "criterion": "use of therapeutic oral or parenteral anticoagulants or thrombolytic agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "therapeutic"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of randomization",
                    "criterion": "stable dose of anticoagulants",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "the use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants >= 14 days at the time of randomization",
                    "criterion": "INR or activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "within therapeutic limits",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient has been on a stable dose of anticoagulants >= 14 days at the time of randomization",
                    "criterion": "stable dose of anticoagulants",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "prophylactic use of anticoagulants is allowed",
                    "criterion": "prophylactic use of anticoagulants",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic peripheral vascular disease",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic peripheral vascular disease",
                    "criterion": "peripheral vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "Serious, non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious, non-healing ... ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious, non-healing ... bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of intra-abdominal abscess =< 6 months prior to randomization; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll",
            "criterions": [
                {
                    "exact_snippets": "History of intra-abdominal abscess =< 6 months prior to randomization",
                    "criterion": "history of intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "prior to randomization",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if the affected area was surgically resected, and there is no further risk to the area, patients may enroll",
                    "criterion": "surgically resected affected area with no further risk",
                    "requirements": [
                        {
                            "requirement_type": "surgical resection of affected area",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "further risk to the area",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known untreated central nervous system (CNS) metastases; Note: patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for this purpose =< 30 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Known untreated central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive",
                    "criterion": "CNS metastasis lesions (radiated or resected)",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "fully treated"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "inactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients are asymptomatic",
                    "criterion": "CNS metastasis symptoms",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "no steroids have been administered for this purpose =< 30 days prior to randomization",
                    "criterion": "steroid administration for CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "administration timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "administration status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known proteinuria defined by >= 2+ protein by urinalysis (UA) or >= 1 gram protein by 24 hour urine collection; Note: Subjects that are >= 2+ or greater on dipstick but < 1 g protein on 24 hour urine ARE eligible to participate",
            "criterions": [
                {
                    "exact_snippets": "Known proteinuria defined by >= 2+ protein by urinalysis (UA) or >= 1 gram protein by 24 hour urine collection",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": ">= 2+ protein by urinalysis (UA)",
                    "criterion": "proteinuria by urinalysis (UA)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">= 1 gram protein by 24 hour urine collection",
                    "criterion": "proteinuria by 24 hour urine collection",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "gram"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation",
            "criterions": [
                {
                    "exact_snippets": "Primary or secondary immunodeficiency (history of or currently active)",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "primary",
                                "secondary"
                            ]
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "history of",
                                "currently active"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or recent (=< 90 days prior to randomization) endoluminal stent in the stomach, bowel, colon or rectum",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (=< 90 days prior to randomization) endoluminal stent in the stomach, bowel, colon or rectum",
                    "criterion": "endoluminal stent in the stomach, bowel, colon or rectum",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Current or recent (=< 28 days prior to randomization) use of sorivudine, brivudine, and St. John?s wort",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (=< 28 days prior to randomization) use of sorivudine",
                    "criterion": "sorivudine use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "current_use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent (=< 28 days prior to randomization) use of brivudine",
                    "criterion": "brivudine use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "current_use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent (=< 28 days prior to randomization) use of ... St. John?s wort",
                    "criterion": "St. John?s wort use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "current_use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}